VNRX News and Press, VolitionRX Limited From 08/02/22

VolitionRx Limited Announces Closing of $6.9 Million Underwritten Public Offering of Common Stock PR Newswire HENDERSON, Nev. , Aug. 2, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, ...

HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, and VolitionRx Limited (NYSE American: VNRX) , a multinational epigen...

FRAMINGHAM, MA / ACCESSWIRE / August 2, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, and VolitionRx Limited (NYSE AMERICAN:VNRX) ("Volition"), a multi...

Gainers: Ayala Pharmaceuticals ( AYLA ) +27% . GeoVax Labs ( GOVX ) +20% . Senti Biosciences ( SNTI ) +17% . Omeros ( OMER ) +15% . CVRx ( CVRX ) +9% . Losers: Nutriband ( NTRB ) -15% . Bausch Health Companies ...

VolitionRx ( NYSE: VNRX ) shares dropped ~14% pre-market on Friday after the epigenetics company priced its $6M underwritten public offering of common stock. The offering consists of 3M shares issued at $2.00 each for a gross proceeds of $6M. Net proceeds will be used ...

VolitionRx Limited Announces Pricing of $6 Million Underwritten Public Offering of Common Stock PR Newswire HENDERSON, Nev. , July 29, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announ...

VolitionRx ( NYSE: VNRX ) on Thursday announced an underwritten public offering of stock . VNRX intends to grant the underwriter a 30-day option to buy up to an additional 15% of the number of shares in the offering at the public offering price. There can be no assuran...

New NETs Data Presented at International Society on Thrombosis and Haemostasis (ISTH) Congress PR Newswire HENDERSON, Nev. , July 13, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company,...

Volition Achieves CE Mark for Nu.Q® NETs Test PR Newswire to aid the detection and evaluation of diseases associated with NETosis AUSTIN, Texas , May 31, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-nati...

VolitionRx Limited (VNRX) Q1 2022 Results Conference Call May 12, 2022 08:30 AM ET Company Participants Scott Powell - Executive Vice President of Investor Relations Cameron Reynolds - President and Chief Executive Officer Tom Butera - Chief Executive Officer, Volition Veterinary Diagnostics ...